Non-alcoholic Fatty Liver Diseases (NAFLD) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

A Trial to Learn if Having ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Conditions:   Nonalcoholic Steatohepatitis;   Genetic Risk Factor Interventions:   Drug: ALN-PNP Dose Level 1;   Drug: ALN-PNP Dose Level 2;   Drug: ALN-PNP Dose Level 3;   Drug: Matching Placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
Conditions:   Non-Alcoholic Fatty Liver Disease;   Fecal Microbiota Transplantation Intervention:   Other: Faecal microbiota transplant Sponsors:   Imperial College London;   King's College London Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

A Trial to Learn if Having ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Conditions:   Nonalcoholic Steatohepatitis;   Genetic Risk Factor Interventions:   Drug: ALN-PNP Dose Level 1;   Drug: ALN-PNP Dose Level 2;   Drug: ALN-PNP Dose Level 3;   Drug: Matching Placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
Conditions:   Non-Alcoholic Fatty Liver Disease;   Fecal Microbiota Transplantation Intervention:   Other: Faecal microbiota transplant Sponsors:   Imperial College London;   King's College London Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

A Trial to Learn if Having ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Conditions:   Nonalcoholic Steatohepatitis;   Genetic Risk Factor Interventions:   Drug: ALN-PNP Dose Level 1;   Drug: ALN-PNP Dose Level 2;   Drug: ALN-PNP Dose Level 3;   Drug: Matching Placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
Conditions:   Non-Alcoholic Fatty Liver Disease;   Fecal Microbiota Transplantation Intervention:   Other: Faecal microbiota transplant Sponsors:   Imperial College London;   King's College London Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

A Trial to Learn if Having ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Conditions:   Nonalcoholic Steatohepatitis;   Genetic Risk Factor Interventions:   Drug: ALN-PNP Dose Level 1;   Drug: ALN-PNP Dose Level 2;   Drug: ALN-PNP Dose Level 3;   Drug: Matching Placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
Conditions:   Non-Alcoholic Fatty Liver Disease;   Fecal Microbiota Transplantation Intervention:   Other: Faecal microbiota transplant Sponsors:   Imperial College London;   King's College London Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

A Trial to Learn if Having ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Conditions:   Nonalcoholic Steatohepatitis;   Genetic Risk Factor Interventions:   Drug: ALN-PNP Dose Level 1;   Drug: ALN-PNP Dose Level 2;   Drug: ALN-PNP Dose Level 3;   Drug: Matching Placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
Conditions:   Non-Alcoholic Fatty Liver Disease;   Fecal Microbiota Transplantation Intervention:   Other: Faecal microbiota transplant Sponsors:   Imperial College London;   King's College London Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials

Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut
Conditions:   CKD;   NAFLD Intervention:   Sponsor:   Muhammad Ameen Abdelrady Abdelaziz Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2023 Category: Research Source Type: clinical trials